Compare Kimberly Clark Corp (KMB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Kimberly Clark Corp trades at $108.57 (market cap $36.48B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.6× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays a 4.67% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| KMB | VRTX | |
|---|---|---|
Market Cap | $36.48B | $132.79B |
Sector | Consumer Staples | Health |
52-Week High | $134.81 | $529.65 |
52-Week Low | $93.05 | $376.62 |
Enterprise Value | $42.04B | $126.92B |
Dividend Yield | 4.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $109.68, up 0.94% with a bullish technical signal. The stock shows strong profitability with 11.79% net margin and 129.43% ROE, though Q2 2026 earnings missed estimates. Recent news highlights China market challenges and dividend stability. Current valuation metrics include P/E of 21.68 and P/S of 2.2, with analyst consensus price target of $113.20 suggesting modest upside potential from current levels.
KMB presents a balanced investment case with solid fundamentals offset by near-term headwinds. The company maintains strong brand positioning and dividend consistency, but faces execution risks from China market disruptions and consumer softness. Wall Street maintains cautious optimism with 61% hold ratings, indicating potential for gradual appreciation if operational challenges are managed effectively.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
